<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/007E0817-B05C-490A-B38A-2EDA79558DDD"><gtr:id>007E0817-B05C-490A-B38A-2EDA79558DDD</gtr:id><gtr:name>Boston University</gtr:name><gtr:address><gtr:line1>One Sherborn Street</gtr:line1><gtr:line2>Boston</gtr:line2><gtr:line3>Massachusetts</gtr:line3><gtr:line4>MA 02215</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Child Health</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/007E0817-B05C-490A-B38A-2EDA79558DDD"><gtr:id>007E0817-B05C-490A-B38A-2EDA79558DDD</gtr:id><gtr:name>Boston University</gtr:name><gtr:address><gtr:line1>One Sherborn Street</gtr:line1><gtr:line2>Boston</gtr:line2><gtr:line3>Massachusetts</gtr:line3><gtr:line4>MA 02215</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/32C75711-61FE-40B1-B099-73E64CC6EF27"><gtr:id>32C75711-61FE-40B1-B099-73E64CC6EF27</gtr:id><gtr:firstName>Hubert</gtr:firstName><gtr:otherNames>Baburaj</gtr:otherNames><gtr:surname>Gaspar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B0FFB06E-0C80-4114-9D30-7040F66F445B"><gtr:id>B0FFB06E-0C80-4114-9D30-7040F66F445B</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Thrasher</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2D126849-B9E6-4168-B571-EEEFBCB29980"><gtr:id>2D126849-B9E6-4168-B571-EEEFBCB29980</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Baum</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0501969"><gtr:id>22ABC3A3-DC0B-40F3-89BB-68B3A9E631AD</gtr:id><gtr:title>Clinical trial of self-inactivating vectors for gene therapy of X-linked Severe Combined Immunodeficiency (SCID-X1)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501969</gtr:grantReference><gtr:abstractText>Gene therapy has the potential to treat a wide range of inherited diseases. Recently, several trials have shown that children with defects of their immune system (often called bubble babies because they are kept in germ free rooms) can be successfully treated in this way by putting new genes into the blood-making factory called bone marrow. However, the way in which the new genes are transplanted into the bone marrow, using modified viruses or vectors, has also been shown in a few children to have unfortunate side-effects. We now know that these arise because the vectors inadvertantly activate other genes that keep the cells in our body healthy. In the worst case, this can cause cancer. However, we also now believe that the risk of this occuring can be substantially limited by improved design of the vectors themselves. Following on from highly encouraging experiments in the laboratory, we would now like to test this strategy in patients for whom coventional bone marrow transplantation is difficult. This will not only provide a new treatment for patients with immune defects, but will provide a platform on which gene therapy can be safely developed for many other diseases.</gtr:abstractText><gtr:technicalSummary>Somatic gene therapy has been proposed as an exciting new therapeutic strategy for treatment of human genetic disease. Four recent studies have demonstrated highly effective gene therapy for the X-linked form of severe combined immunodeficiency (SCID-X1) and ADA-deficiency, using mammalian retroviruses to deliver the therapeutic genes into haematopoietic stem cells ex vivo. SCID-X1, caused by mutations in the common cytokine receptor gamma chain (gamma-c), is invariably fatal in the absence of therapeutic bone marrow transplantation. In the presence of HLA-matched family donors, the majority of patients can expect to be cured. For other donor sources, particularly parental, success rates are reduced, and full restoration of immunity is often not achieved. We have recently successfully treated seven children with molecularly defined SCID-X1 by gene transfer to bone marrow CD34+ cells using a gibbon ape leukaemia virus (GALV)-pseudotyped gammaretroviral vector. However, the development of leukaemia in patients enrolled in a similar trial has highlighted the risk of inadvertent gene activation through insertional mutagenesis. We have therefore explored strategies to minimise this risk by development of gammaretroviral vectors that are deleted for powerful endogenous viral enhancer sequences (SIN). We are currently in the final phases of testing these vectors, but have shown that they retain the capacity for correction of the SCID-X1 disease phenotype in animal models, and have a significantly reduced mutagenic potential in vitro. Here we propose a clinical trial for testing these novel vectors in human patients. This will be the first clinical study using SIN gammaretroviral technology, and will hopefully establish a solid platform for the development of safe and efficacious gene therapy in many other disease types.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-01</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>764001</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boston University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Overseas clinical trials</gtr:description><gtr:id>E569AAB5-EC1D-4BF9-B20E-E1B61FFDE9AF</gtr:id><gtr:impact>Clinical trials submitted to regulatory authorities in Europe and US. Permissions granted and recruiting in progress.</gtr:impact><gtr:partnerContribution>preclinical data</gtr:partnerContribution><gtr:piContribution>pre clinical data vector development and proof of principle</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Necker Hospital</gtr:department><gtr:description>Overseas clinical trials</gtr:description><gtr:id>72F62BFC-DC9A-4F9D-A6F2-D224005F83A9</gtr:id><gtr:impact>Clinical trials submitted to regulatory authorities in Europe and US. Permissions granted and recruiting in progress.</gtr:impact><gtr:partnerContribution>preclinical data</gtr:partnerContribution><gtr:piContribution>pre clinical data vector development and proof of principle</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cologne Summer School</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>47A0F7A2-3C1D-48B7-8702-384395A1D347</gtr:id><gtr:impact>University of Cologne Summer School: Gene Therapy and Regenerative Medicine, 3rd-5th September 2012
&amp;quot;Learning from Gene Therapies for Immunodeficiencies&amp;quot;


Generated much interest</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2010,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSGT/BSGCT</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F841BE7A-2924-42EF-9A17-CBA550C6C762</gtr:id><gtr:impact>British Society for Gene Therapy, Warwick, March 2007
Successful bone marrow gene therapy for inherited immunodeficiency

British Society for Gene Therapy, Edinburgh, April 2008
Severe combined immunodeficiency: clinical update and development of safer protocols

Joint BSGT/ESGCT meeting, Brighton 27th-31st October 2011
&amp;quot;Gene therapy for immunodeficiency&amp;quot; 


Much interest</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2007,2008,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK-Israel Regenerative Medicine meetings, Israel</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BB908B75-B13F-418F-BC24-052C705F7852</gtr:id><gtr:impact>UK-Israel Regenerative Medicine Conference and Launch of the BIRAX Regenerative Medicine Initiative, Beer Sheva Israel, 22-23 November 2011
&amp;quot;Gene Therapy for Immunodeficiency&amp;quot; 


Generated much interest, launch of BIRAX Regenerative Medicine Initiative.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK National Stem Cell Network meeting, York</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3C2C0E9F-E478-44C3-9E60-B7EBB4DCD661</gtr:id><gtr:impact>UK National Stem Cell Network meeting, York 30-31 March 2011
&amp;quot;Successful genetic therapy for immunodeficiency&amp;quot;


Networking</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK-Japan Gene Therapy Workshop, Tokyo</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EA38AC4A-4DE7-43B2-B031-CF4AC8985A42</gtr:id><gtr:impact>2nd UK-Japan Gene Therapy Workshop, Tokyo October 2006
Gene therapy strategies for immunodeficiencies

Networking</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>German Society for Gene Therapy Summer School, Cologne</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EC6AAA54-44D9-4B4C-8B05-9707BAC83D61</gtr:id><gtr:impact>Vector Development and Gene Therapy Course, German Society for Gene Therapy, Cologne, September 2009.
&amp;quot;Gene Therapy of Immune Deficiencies&amp;quot;


Excellent feedback. Much interest generated</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Inspiring Careers in Science</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CE3EAD63-A0D4-486E-BD71-597EC7866B64</gtr:id><gtr:impact>Inspiring Careers in Science - Educational Fellowship UCL Awayday, 7th May 2013.
Q&amp;amp;A session &amp;quot;Moral Dilemmas - how will rapid advances in science and medicine affect you?&amp;quot;


Very positive response and feedback. Enquiries from other schools regarding future events</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Tohoku University Hospital, Japan</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A22F17FA-D449-4567-9683-B2C3B92B80EA</gtr:id><gtr:impact>Tohoku University Hospital, Japan, December 2007
Update on gene therapy trials for SCID


Generated much interest</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Primary Immune Deficiency Treatment Consortium (PIDTC)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C08FD708-6783-47F5-B0D4-2639EF3148D5</gtr:id><gtr:impact>Addressing Primary Immune Deficiency Treatment Consortium (PIDTC) &amp;quot;Vector optimization and strategies for targeted gene repair&amp;quot;

Networking</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Hong Kong</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7600DB05-389B-47A7-AB62-55B4C175A8C8</gtr:id><gtr:impact>Faculty of Medicine Departmental Research Meeting, University of Hong Kong, 22 January 2013
&amp;quot;A journey through WAS: Actin Cytoskeleton and the Immune Response&amp;quot;

Faculty of Medicine Departmental Grand Round, University of Hong Kong, 24 January 2013
&amp;quot;Current Clinical Applications of Gene Therapy in Childhood Diseases&amp;quot;

Stem Cell and Regenerative Medicine Consortium seminar, University of Hong Kong, 24 January 2013.
&amp;quot;Gene Therapy for Primary Immunodeficiencies: From Bench to Clinic&amp;quot;


Arrangements initiated for visiting clinician from Hong Kong to work in our labs for 2 years 2010-2012, and for Professorial visit by Prof Yu-Lung Lau in 2013.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stem Cell Clonality and Genotoxicity Retreat</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>78D9CD2E-76DA-48C2-A685-C2B45344EEC6</gtr:id><gtr:impact>4th Stem Cell Clonality and Genotoxicity Retreat, Boston, June 2008
X-linked severe combined immune deficiency trial / Clinical Trials for SCID past and future.

5th Stem cell clonality and genotoxicity retreat, ESGCT Hannover November 2009
&amp;quot;Gene therapy of severe combined immunodeficiency&amp;quot;

Stem Cell Clonality and Genome Stability Retreat, Madrid 24-25th October 2013
&amp;quot;Update on SCID-X1 Gene Therapy&amp;quot;


Always successful meetings generating much discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2008,2009,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>JMF Network, Berlin</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AC0E3AB6-966A-4AC1-80EF-538F50941EC5</gtr:id><gtr:impact>Jeffrey Modell Centres Network, Berlin, 17-21 July 2013
&amp;quot;Progress in gene therapy from bench to clinic&amp;quot;


Opportunity for networking with other JMF Centres</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IATI Symposium, Granada</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>21C6C6C6-AB8C-4F4A-B997-71943A6374D7</gtr:id><gtr:impact>IATI Symposium, Granada, 28th-29th June 2012
&amp;quot;Gene Therapies for Immunodeficiencies&amp;quot; 


No feedback available to me</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Transatlantic Gene Therapy Consortium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>767189C8-9C32-4E64-BCA5-883817D1F26E</gtr:id><gtr:impact>Transatlantic Gene Therapy Consortium, San Diego, May 2009
&amp;quot;Vector Developments for PID&amp;quot;

Transatlantic Gene Therapy Consortium, 15th May 2012
&amp;quot;Update on Trials for SCID-X1&amp;quot;


Networking</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2009,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Children's Hospital of Chongqing Medical University, China</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>51E774AF-CE08-4CEE-8523-BC2F2226DC03</gtr:id><gtr:impact>Children's Hospital of Chongqing Medical University, China, October 2010
&amp;quot;Gene therapy for immunodeficiency&amp;quot;


Very positive feedback.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>97217</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Great Ormond Street Biomedical Research Centre</gtr:department><gtr:description>BRC (ADA)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Great Ormond Street Hospital (GOSH)</gtr:fundingOrg><gtr:id>5152DDF5-23D0-44EC-ADEA-65A447918E78</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1226390</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Developmental Pathway Clinical Studies Grant (ADA)</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K015427/1</gtr:fundingRef><gtr:id>E5033DF1-A2A4-40A7-93D2-2C788E055CFA</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>stem cell gene therapy currently part of international multicentre study, MRC funded.</gtr:description><gtr:id>FD6A091C-35F3-4E82-91CD-E816F564675E</gtr:id><gtr:impact>Improved survival compared with conventional therapies</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Gene therapy for X-linked SCID</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:ukcrnIsctnId>UKCRN 4601</gtr:ukcrnIsctnId><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=4601</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>retroviral vector for gene therapy</gtr:description><gtr:id>0AF46F4F-467C-4B97-AC1E-E44BB02F56A2</gtr:id><gtr:impact>results awaited from clinical trial</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>retroviral vector</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:ukcrnIsctnId>CRN7313</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>therapeutic retrovirus for gene therapy of SCID</gtr:description><gtr:id>82711650-8410-4648-AFA6-446F78A452E3</gtr:id><gtr:impact>First in man trial open</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>SIN gammaretroviral vector</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C408E6E9-D69F-4205-8324-05F9BD6EF4C9"><gtr:id>C408E6E9-D69F-4205-8324-05F9BD6EF4C9</gtr:id><gtr:title>A modified ?-retrovirus vector for X-linked severe combined immunodeficiency.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/53779ddf971a469181d87260c221344b"><gtr:id>53779ddf971a469181d87260c221344b</gtr:id><gtr:otherNames>Hacein-Bey-Abina S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B268EFF1-9211-41CE-85B2-3ED560CF92FD"><gtr:id>B268EFF1-9211-41CE-85B2-3ED560CF92FD</gtr:id><gtr:title>Gene therapy for primary immunodeficiencies.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/389bb18dd04f9608cc69e03741418009"><gtr:id>389bb18dd04f9608cc69e03741418009</gtr:id><gtr:otherNames>Rivat C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C57B4F30-2F85-48AB-9AE4-A9A9666F309B"><gtr:id>C57B4F30-2F85-48AB-9AE4-A9A9666F309B</gtr:id><gtr:title>Current progress on gene therapy for primary immunodeficiencies.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/917fedf7d4ac4a5d4fbb9db6070723d7"><gtr:id>917fedf7d4ac4a5d4fbb9db6070723d7</gtr:id><gtr:otherNames>Zhang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/92D3362C-2938-49A0-9302-23C6F9AFA90C"><gtr:id>92D3362C-2938-49A0-9302-23C6F9AFA90C</gtr:id><gtr:title>Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1809274402a5f43e1a80a137e1986a33"><gtr:id>1809274402a5f43e1a80a137e1986a33</gtr:id><gtr:otherNames>Zhang F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/989ED315-CF97-407B-BC45-3D745295E12D"><gtr:id>989ED315-CF97-407B-BC45-3D745295E12D</gtr:id><gtr:title>Gene therapy for PIDs: progress, pitfalls and prospects.</gtr:title><gtr:parentPublicationTitle>Gene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d9e1cd243ee5a92b5cfb11d830864884"><gtr:id>d9e1cd243ee5a92b5cfb11d830864884</gtr:id><gtr:otherNames>Mukherjee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0378-1119</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F2286D67-366B-4EFB-B5D0-AF2350741FFA"><gtr:id>F2286D67-366B-4EFB-B5D0-AF2350741FFA</gtr:id><gtr:title>Scale-up and manufacturing of clinical-grade self-inactivating ?-retroviral vectors by transient transfection.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bc09d2dab3b6b1915662c622e57b96f5"><gtr:id>bc09d2dab3b6b1915662c622e57b96f5</gtr:id><gtr:otherNames>van der Loo JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D29DF747-0871-4CF9-BA4A-23CBF6FCFB8D"><gtr:id>D29DF747-0871-4CF9-BA4A-23CBF6FCFB8D</gtr:id><gtr:title>Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dd17b216b843d6a2bf8cc2768bf4e375"><gtr:id>dd17b216b843d6a2bf8cc2768bf4e375</gtr:id><gtr:otherNames>Gaspar HB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D690BCE-321E-4573-B317-7E3DCF9F2FEE"><gtr:id>0D690BCE-321E-4573-B317-7E3DCF9F2FEE</gtr:id><gtr:title>Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5fc8ce853da931230f854eccd5393ac9"><gtr:id>5fc8ce853da931230f854eccd5393ac9</gtr:id><gtr:otherNames>Huston MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89EE9386-3B9F-4FE8-A1DD-653213DE210B"><gtr:id>89EE9386-3B9F-4FE8-A1DD-653213DE210B</gtr:id><gtr:title>Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/79e56a4a7153c133feb4df23e4a94102"><gtr:id>79e56a4a7153c133feb4df23e4a94102</gtr:id><gtr:otherNames>Thornhill SI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C5E5669-5509-4D47-810A-A12A3375820F"><gtr:id>3C5E5669-5509-4D47-810A-A12A3375820F</gtr:id><gtr:title>A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8004d1b90f19b207a63d2f9100777b0c"><gtr:id>8004d1b90f19b207a63d2f9100777b0c</gtr:id><gtr:otherNames>Loew R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A1052969-6650-42D1-9D36-5ED27E3FDE12"><gtr:id>A1052969-6650-42D1-9D36-5ED27E3FDE12</gtr:id><gtr:title>Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bc09d2dab3b6b1915662c622e57b96f5"><gtr:id>bc09d2dab3b6b1915662c622e57b96f5</gtr:id><gtr:otherNames>van der Loo JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501969</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>